Rhythm Biosciences Limited (ASX:RHYOA)

Australia · Delayed Price · Currency is AUD

0.0200

0.00 (0.00%)

At close: Sep 3, 2026

Market Cap	30.79M +16.5%
Revenue (ttm)	1.74M -47.7%
Net Income	-5.93M
EPS	-0.02
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,032
Open	0.0200
Previous Close	n/a
Day's Range	0.0200 - 0.0200
52-Week Range	0.0080 - 0.1300
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 14, 2026

About Rhythm Biosciences

Rhythm Biosciences Limited, a medical diagnostics company, develops and commercialises medical diagnostic tests for cancer detection in Australia and the United States. The company offers ColoSTAT, a blood test for the early detection of colorectal cancer; and geneType, a personalized predictive test for predicting risk of chronic disease development. Rhythm Biosciences Limited was incorporated in 2017 and is headquartered in Parkville, Australia. [Read more]

Industry In Vitro and In Vivo Diagnostic Substances

Founded 2017

Country Australia

Stock Exchange Australian Securities Exchange

Ticker Symbol RHYOA

Financial Performance

In fiscal year 2026, Rhythm Biosciences's revenue was 1.74 million, a decrease of -47.67% compared to the previous year's 3.33 million. Losses were -5.93 million, 54.9% more than in 2025.

Financial Statements